Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib Combined With Tislelizumab in Advanced NSCLC With Neuroendocrine Differentiation
NCT06414915Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jun 2024
- Primary completion
- Jun 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of surufatinib in non-small cell lung cancer (NSCLC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
surufatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06414915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06414915.